Clinical Trial Update: Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on the validity and security of Reh-acteoside therapy for IgA nephropathy, involving Phase 2 and Phase 3 studies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Reh-acteoside therapy

Snippet

Sponsor: Sun Yat-sen University | Conditions: IGA Nephropathy | Phase 2, Phase 3 | Status: UNKNOWN